Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
Alu-Cap is recommended for use as a phosphate binding agent in the management of renal failure. It may also be used as an antacid.
Adults and children: The dosage must be selected in accordance with individual patient requirements, and may range from 4 to 20 capsules of Alu-Cap daily (approximately 2 to 10 g dried aluminium hydroxide gel), taken with meals.
Adults: One Alu-Cap four times daily and on retiring.
Children: Alu-Cap is not suitable for antacid therapy in children.
Elderly: No special dosage recommendations are made for elderly patients.
A single massive dose of aluminium hydroxide is unlikely to have harmful sequelae, as aluminium is not absorbed systemically to any great extent. Gastric lavage should be administered, followed by a mild aperient if required.
Excessive long-term dosage may cause phosphate depletion, manifested in muscle weakness, anorexia and malaise. If left unchecked this condition may give rise to osteomalacia, osteoporosis and urinary calculi.
Shelf life: 5 years.
Store the capsules below 30°C.
Amber glass bottles with screw cap containing 120 capsules.
None.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
